Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Add To Watchlist

Recent & Breaking News (OTCQX:RHHBY)

The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble

Benzinga.com November 29, 2016

Wall Street's M&A Chatter From November 28

Benzinga.com November 29, 2016

5 BioPharma Catalysts Expected Around Christmas

Benzinga.com November 27, 2016

The Market In 5 Minutes: Dow, S&P 500 Trading At All-Time Highs

Benzinga.com November 22, 2016

Wall Street's M&A Chatter From November 21

Benzinga.com November 22, 2016

Roche launches DISCOVERY 5-Plex procedure for cancer research applications

PR Newswire Europe Non Regulatory November 21, 2016

Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis

Business Wire November 12, 2016

FDA approves Roche's VENTANA ALK (D5F3) CDx Assay for use on the VENTANA BenchMark ULTRA system

PR Newswire Europe Non Regulatory November 7, 2016

Roche launches new RNA HyperPrep product line

PR Newswire Europe Non Regulatory November 7, 2016

Genentech Showcases New Clinical Data across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting

Business Wire November 3, 2016

Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting

Business Wire November 2, 2016

Roche announces FDA approval for VENTANA PD-L1 (SP142) Assay to support immunotherapy treatment decisions in lung cancer

PR Newswire Europe Non Regulatory October 27, 2016

LabCorp is first US laboratory to offer molecular testing with new fully automated cobas 8800 system from Roche

PR Newswire October 24, 2016

Roche receives FDA approval for fully automated blood screening assay on the cobas® 6800/8800 Systems

PR Newswire October 21, 2016

Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916

PR Newswire October 20, 2016

FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Business Wire October 18, 2016

Benzinga's M&A Chatter for Monday, October 17, 2016

Benzinga.com October 17, 2016

FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Business Wire October 14, 2016

FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization

Business Wire October 11, 2016

Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III Study

Business Wire October 9, 2016